

North Central Cancer Treatment Group

N0272 Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) In Treatment of  
Recurrent Oligodendroglioma and Mixed Oligoastrocytoma

Status Change – February 1, 2008

**NOTICE OF STATUS CHANGE**

Study 1, Arm C (EAC's patients) has met accrual to cohort 3. Therefore  
Study 1, Arm C (EAC's patients) is temporarily suspended to patient accrual effective  
immediately, February 1, 2008. Patient entry will not be permitted until further notification  
is issued.

**Please retain this notice with the protocol.**